Key result
Available evidence does not indicate a superior effect on clinical outcomes in heart failure with reduced ejection fraction or a greater reduction in blood pressure in hypertension for nebivolol compared with bisoprolol.
Why the study?
Whether the additional vasodilator actions of nebivolol compared with bisoprolol influence its effectiveness in managing HFrEF, IHD, and hypertension remained unclear given a lack of head-to-head trials.
Does nebivolol improve clinical outcomes or blood pressure reduction compared to bisoprolol in patients with cardiovascular disease?
Does nebivolol improve clinical outcomes or blood pressure reduction compared to bisoprolol in patients with cardiovascular disease?
Despite its additional vasodilator properties, nebivolol does not appear to offer clear clinical advantages over bisoprolol in patients with HFrEF or hypertension based on current evidence.
Answers are grounded in this paper and cite their sources.
Evidence does not support preferring nebivolol over bisoprolol; leaves open whether randomized trials would show outcome differences.
-adrenoceptor antagonists, with clinical indications in many countries within the management of heart failure with reduced left ventricular ejection fraction (HFrEF), ischaemic heart disease (IHD), and hypertension. Nebivolol has additional vasodilator actions, related to enhanced release of NO in the vascular wall. In principle, this additional mechanism compared with bisoprolol might lead to more potent vasodilatation, which in turn might influence the effectiveness of nebivolol in the management of HFrEF, IHD and hypertension. In this article, we review the therapeutic properties of bisoprolol and nebivolol, as representatives of "second generation" and "third generation" β-blockers, respectively. Although head-to-head trials are largely lacking, there is no clear indication from published studies of an additional effect of nebivolol on clinical outcomes in patients with HFrEF or the magnitude of reductions of BP in patients with hypertension.
No takes yet. Share an insight, caveat, or question.
AlHabeeb et al. (2021) conducted a review in Cardiovascular Disease. Bisoprolol and Nebivolol was evaluated. Available evidence does not indicate a superior effect on clinical outcomes in heart failure with reduced ejection fraction or a greater reduction in blood pressure in hypertension for nebivolol compared with bisoprolol.
Synapse has enriched 10 related papers. Consider them for comparative context: